Effects of Weight Loss on FGF-21 in Human Subjects: An Exploratory Study

被引:9
|
作者
Headland, Michelle L. [1 ,2 ,3 ]
Clifton, Peter M. [1 ,2 ,3 ]
Keogh, Jennifer B. [1 ,2 ,3 ]
机构
[1] Univ South Australia, Sch Pharm & Med Sci, Frome Rd, Adelaide, SA 5000, Australia
[2] Univ South Australia, ARENA, Frome Rd, Adelaide, SA 5000, Australia
[3] Univ South Australia, Sansom Inst Hlth Res, Frome Rd, Adelaide, SA 5000, Australia
关键词
intermittent energy restriction; fibroblast growth factor-21; weight loss; FIBROBLAST GROWTH FACTOR-21; Y GASTRIC BYPASS; PPAR-ALPHA; SERUM CONCENTRATIONS; HEPATIC GLUCONEOGENESIS; FASTING RESPONSE; FGF21; REGULATOR; METABOLISM; OBESITY;
D O I
10.3390/ijerph16234877
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Fibroblast growth factor-21 (FGF-21), is a protein involved in cell growth and differentiation, development, wound repair and metabolism. Research looking at the impact of weight loss on FGF-21 levels is limited. The objective of this exploratory study was to determine changes in serum FGF-21 levels following weight loss induced by either continuous energy restriction or intermittent energy restriction. A sub cohort of participants who completed a 12-month dietary intervention trial following continuous energy restriction, or a week-on week-off energy restriction pattern, were selected for analysis. FGF-21 levels were not altered by weight loss and were not correlated with body weight or BMI at baseline or 12 months. Weight loss after 12 months either through continuous energy restriction or intermittent energy restriction was -5.9 +/- 4.5 and -4.9 +/- 3.4 kg, respectively. There was no change in FGF-21 levels, 0.3 +/- 0.9 and 0.04 +/- 0.2 ng/mL (p = 0.2). In conclusion, weight loss in healthy overweight or obesity subjects did not affect FGF-21 levels.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Fibroblast growth factor-21 (FGF-21) synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes
    Brenner, M. B.
    Lee, D. V.
    Bernardo, B.
    Talukdar, S.
    DIABETOLOGIA, 2012, 55 : S226 - S226
  • [32] Liver FGF21 Contributes to the Weight Lowering Effects of Liraglutide
    Le, Thao
    Ayala, Julio
    OBESITY, 2020, 28 : 120 - 120
  • [33] Genetic Variant Close to FGF-21 Is Associated with Dietary Macronutrient Intake and Modifies Effects of a Weight-Loss Diet on 2-Year Changes of Body Composition and Fat Distribution: The POUNDS LOST Trial
    Heianza, Yoriko
    Huang, Tao
    Wang, Tiange
    Sun, Dianjianyi
    Smith, Steven R.
    Bray, George A.
    Sacks, Frank M.
    Qi, Lu
    DIABETES, 2016, 65 : A60 - A60
  • [34] INCREASED CIRCULATING LEVELS AND PERIPHERAL TISSUE PROMOTER DNA METHYLATION OF THE HORMONE FGF-21 FOLLOWING ACUTE SLEEP LOSS IN HUMANS
    Espes, Daniel
    Carlson, Per-Ola
    Benedict, Christian
    Cedernaes, Jonathan
    SLEEP, 2019, 42
  • [35] The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
    Gaich, Gregory
    Chien, Jenny Y.
    Fu, Haoda
    Glass, Leonard C.
    Deeg, Mark A.
    Holland, William L.
    Kharitonenkov, Alexei
    Bumol, Thomas
    Schilske, Holger K.
    Moller, David E.
    CELL METABOLISM, 2013, 18 (03) : 333 - 340
  • [36] Key role for FGF21 in GLP1-mediated weight loss
    David Holmes
    Nature Reviews Endocrinology, 2016, 12 (12) : 688 - 688
  • [37] THE EXPRESSION AND CLINIC STUDY OF FGF-21 AND NT-PROBNP IN THE MAINTENANCE PERITONEAL DIALYSIS COMBINED WITH DIABETIC NEPHROPATHY
    Xu, Tao
    Cheng, Qiao
    Wang, Niansong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 473 - 474
  • [38] Alteration of BDNF, SPARC, FGF-21, and GDF-15 circulating levels after 1 year of anti-obesity treatments and their association with 1-year weight loss
    Kusuma Chaiyasoot
    Nanta Khumkhana
    Wanjan Deekum
    Chartchai Chaichana
    Voraboot Taweerutchana
    Nicha Srisuworanan
    Pornpoj Pramyothin
    Endocrine, 2023, 82 : 57 - 68
  • [39] Alteration of BDNF, SPARC, FGF-21, and GDF-15 circulating levels after 1 year of anti-obesity treatments and their association with 1-year weight loss
    Chaiyasoot, Kusuma
    Khumkhana, Nanta
    Deekum, Wanjan
    Chaichana, Chartchai
    Taweerutchana, Voraboot
    Srisuworanan, Nicha
    Pramyothin, Pornpoj
    ENDOCRINE, 2023, 82 (01) : 57 - 68
  • [40] Hesperidin abrogates bisphenol A endocrine disruption through binding with fibroblast growth factor 21 (FGF-21), α-amylase and α-glucosidase: an in silico molecular study
    Aja, P. M.
    Awoke, J. N.
    Agu, P. C.
    Adegboyega, A. E.
    Ezeh, E. M.
    Igwenyi, I. O.
    Orji, O. U.
    Ani, O. G.
    Ale, B. A.
    Ibiam, U. A.
    JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY, 2022, 20 (01)